Connect
MJA
MJA

A funding model for public-good clinical trials

Ingrid M Winship, John McNeil and R John Simes
Med J Aust 2013; 199 (2): 90-91. || doi: 10.5694/mja13.10381
Published online: 22 July 2013

The cost of clinical trials is rising but is still much less than the cost of not doing trials

Clinical trials have led to significant advances in health outcomes. For example, much of the continued decline in cardiovascular mortality since 2000 has been attributed to the evidence that established the various treatment strategies now in common use.1 However, as the costs of both medical care and clinical trials continue to rise, are our current clinical trials good value for money? In this article, the last in a series based on the MJA Clinical Trials Research Summit, we discuss the need for an innovative funding model for investigator-led clinical trials.

  • Ingrid M Winship1
  • John McNeil2
  • R John Simes3

  • 1 Melbourne Health, Melbourne, VIC.
  • 2 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC.
  • 3 NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW.

Correspondence: john@ctc.usyd.edu.au

Acknowledgements: 

We acknowledge Rhana Pike from the NHMRC Clinical Trials Centre for assistance with the manuscript.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.